Keenova Therapeutics plc: Chronic Pain trials
The registry lists 10 Chronic Pain studies with Keenova Therapeutics plc as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 3 10(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain PatientsTerminatedNCT02321319Phase 3Results posted
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric SubjectsTerminatedNCT00765856Phase 3Results posted
- A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) PainCompletedNCT00631319Phase 3Results posted
- Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back PainCompletedNCT00549042Phase 3Results posted
- Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced ChildrenSuspendedNCT04681027Phase 3
- Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric SubjectsWithdrawnNCT01206907Phase 3
- Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic PainCompletedNCT00911287Phase 3
- Oxymorphone Extended Release in Patients With Cancer or Neuropathic PainCompletedNCT00911261Phase 3
- Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant PainCompletedNCT00226421Phase 3
- Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainCompletedNCT00225797Phase 3